Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oblimersen + dexamethasone
- Development stage
- Unknown
- Lead developer
- Genta
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous (oblimersen), Oral (dexamethasone)
01
Overview
**Oblimersen + dexamethasone** is a combination regimen consisting of *oblimersen sodium* (an antisense oligonucleotide) and *dexamethasone* (a synthetic glucocorticoid). Oblimersen specifically binds to Bcl-2 mRNA, leading to decreased production of the anti-apoptotic Bcl-2 protein. This mechanism aims to sensitize malignant plasma cells (especially in multiple myeloma) that often overexpress Bcl-2, resulting in resistance to apoptosis and chemotherapy. Dexamethasone serves as an antineoplastic and immunosuppressive agent, commonly used in the treatment of hematologic malignancies. Experimental and clinical data indicate that combining oblimersen with dexamethasone enhances apoptosis in resistant myeloma cells, though a phase III trial in relapsed/refractory multiple myeloma did not show a statistically significant benefit over dexamethasone alone[1][2][3][4].
- Other names
- oblimersen sodium + dexamethasone
02
Targets
BCL-2 (BCL-2 family)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on oblimersen + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oblimersen + dexamethasone.